No Data
Will pay over 30 million equity dispute amounts. Getein Biotech, Inc has issued multiple lawsuit announcements in the past four months | Brief announcement.
① Getein Biotech, Inc and nine minority shareholders of Jingchuan Diagnostics, including Wuhan Boruihong, have received a final judgment in their equity acquisition dispute. ② According to the judgment, Getein Biotech, Inc will pay over 30 million yuan for the acquisition.
Retail Investors Among Getein Biotech, Inc's (SHSE:603387) Largest Stockholders and Were Hit After Last Week's 9.5% Price Drop
Improved Earnings Required Before Getein Biotech, Inc (SHSE:603387) Shares Find Their Feet
Getein Biotech, Inc (603387.SH): The company's Metis6000 fully automatic biochemical immune assembly line installed more than 20 units in the third quarter of 2024.
Gelonghui, November 12th | Getein Biotech, Inc. (603387.SH) stated at the performance online conference that the company's Metis6000 fully automatic biochemical immune pipeline had installed over 20 units in the third quarter of 2024, over 70 units in the first three quarters, and a total of over 120 units installed since going public. The units are mainly distributed in the inspection department, with a small number in the emergency department and endocrine department. Among them, the installation in tertiary hospitals accounts for over 30%, while in secondary hospitals, it accounts for over 40%. The terminals mainly cover testing items such as liver function, tumor markers, myocardium, infectious diseases, inflammation, sex hormones, glucose metabolism, gastric function, bone metabolism, and others.
Basal Egg Organism: Basal Egg Organism: Third Quarter Report 2024
Egg Biosciences: third quarter report 2024
Getein Biotech, Inc (SHSE:603387) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough
